Cansino Biologics, Inc. Class ASSE: 688185

-- Announcement on Obtaining Notice of Approval for Drug Clinical Trial for Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell)

· Issued by Cansino Biologics, Inc. Class A via Shanghai Stock Exchange
Announcement on Obtaining Notice of Approval for Drug Clinical Trial for Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell)

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis